sulfur
Approved
Sep 17, 1940
Mercury(I) iodide is a chemical compound that has been used as a drug in the 19th century, sometimes under the contemporary name of 'protiodide of mercury'. Mercury(I) iodide was used to treat a wide range of conditions; everything from acne to kidney disease and in particular was the treatment of choice for syphilis. It was available over the counter at any drugstore in the world, the most common form being a concoction of protiodide, licorice, glycerin, and marshmallow. Taken orally, and in low doses, protiodide causes excessive salivation, fetid breath, spongy and bleeding gums, and sore teeth. Excessive use or an overdose causes physical weakness, loss of teeth, hemolysing (destruction of the red blood cells) of the blood and necrosis of the bones and tissues of the body. Early signs of an overdose or excessive use are muscular tremors, chorea, and locomotor ataxia. Violent bloody vomiting and voiding also occur. — NCATS
Clinical trial activity
4 trials · 6 clinical orgs · 1 marketing orgs
Earliest trial started Apr 1, 2009 (NCT00877409)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Approval history
- approvedSep 17, 1940
- approvedSep 17, 1940
Chemistry & pharmacology
SMILES
S1SSSSSSS1- Mol. weight
- 256.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaSulfur ↗
- NCATS70FD1KFU70 ↗
- ChEMBLCHEMBL2105487 ↗
- ChEMBLCHEMBL1235452 ↗
Also known as
- acnaveen
- acnil
- bensulfoid
- bensulfoid
- cuticura
- dome-acne
- eskamel
- liquamat
- liquamat
- meted
- sastid
- sastid
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur
- sulfur compounds
- sulfur compounds
- sulfur precipitated
- sulfur precipitated
- sulfur, precipitated
- sulfur, precipitated
- sulfur soap
- sulfur soap
- sulfur, sublimed
- sulfur, sublimed
- sulphur
- sulphur
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06170333 | Phase 4 | Aug 25, 2023 | Padjadjaran University |
| NCT06396507 | Phase 3 | Mar 15, 2022 | Damascus University, Tishreen University, University of Aleppo |
| NCT01260571 | Phase 4 | Jan 1, 2011 | Zurita Laboratorio Farmaceutico Ltda. |
| NCT00877409 | Phase 3 | Apr 1, 2009 | Medcin Instituto da Pele, Zurita Laboratorio Farmaceutico Ltda. |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zurita Laboratorio Farmaceutico Ltda. | For profit | 2 | 2 | 2 | 2009 |
| Damascus University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Medcin Instituto da Pele | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Padjadjaran University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Tishreen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Aleppo | Academic/Hospital | 1 | 0 | 1 | 2022 |